---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-062780"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:33:16.394202+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protara Q2 net loss $11.3M; TARA-002 trials on track; cash runway into 2025

## Summary
- Net loss Q2 2023: $11.3M ($1.00/share) vs $8.5M ($0.76) in Q2 2022
- Cash, equivalents $80.4M; expected to fund operations into 2025
- R&D expenses $7.2M, up from $3.1M YoY on TARA-002 clinical costs
- Preliminary TARA-002 NMIBC expansion results expected 1H24; ADVANCED-2 and LM trial start 4Q23

## SEC filing metadata
- accession: 0001213900-23-062780
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390023062780/0001213900-23-062780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390023062780/ea182633-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-062780
- JSON: https://secwatch.observer/filing/0001213900-23-062780.json
- Plain text: https://secwatch.observer/filing/0001213900-23-062780.txt

## Key facts
- Earnings Releases
  Protara Therapeutics, Inc. reported second quarter ended June 30, 2023 results: net income net loss of $11.3 million, or $1.00 per share, EPS $1.00 per share.
  - Period: second quarter ended June 30, 2023
  - Net income: net loss of $11.3 million, or $1.00 per share
  - EPS: $1.00 per share
  - Result: reported results
  source text: For the second quarter of 2023, Protara reported a net loss of $11.3 million, or $1.00 per share, compared with a net loss of $8.5 million, or $0.76 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390023062780/0001213900-23-062780-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.